Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer

International Journal of Urology

Volumn 22, Issue 5, 2015, Pages 490-494

  Muto, Satoru ^a   Abe, Hideyuki ^b   Noguchi, Takahiro ^a   Sugiura, Sho ichiro ^a   Kitamura, Kousuke ^a   Isotani, Shuji ^a   Ide, Hisamitsu ^a   Yamaguchi, Raizo ^a   Kamai, Takao ^b   Horie, Shigeo ^c  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Chemotherapy; Gemcitabine; Maintenance therapy; Metastasis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTINEOPLASTIC METAL COMPLEX; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; EPIRUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PALLIATIVE THERAPY; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR; VISCERAL METASTASIS; ANALOGS AND DERIVATIVES; MIDDLE AGED; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84928773375     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12727     Document Type: Article

References (25)

1. Galsky MD, Moshier E, Krege S et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 2013; 119: 3012-9.
2. Stenzl A, Cowan NC, De Santis M et al. Treatment of muscle-invasive and metastatic bladder cancer. update of the EAU guidelines. Eur. Urol. 2011; 59: 1009-18.
3. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 1999; 17: 3173-81.
4. Shelley MD, Cleves A, Wilt TJ, Mason MD. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. BJU Int. 2011; 108: 168-79.
5. S LH, Gospodariwicz M, Wittekind C (eds). TNM classification of malignant tumors. UICC International Union Against Cancer, 7th edn. Chichester: Wiley-Blackwell, 2009; pp.262-5.
6. Akaza H, Naito S, Usami M et al. Efficacy and Safety of Gemcitabine Monotherapy in Patients with Transitional Cell Carcinoma after Cisplatin-Containing Therapy: A Japanese Experience. Jpn. J. Clin. Oncol. 2007; 37: 201-6.
7. R Development Core Team. R. a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2011.
8. Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit. Rev. Oncol. Hematol. 2003; 46: S105-15.
9. von der Maase H, Sengelov L, Roberts JT et al. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. J. Clin. Oncol. 2005; 23: 4602-8.
10. Rosenberg JE, Carroll PR, Small EJ. Update of chemotherapy for advanced bladder cancer. J. Urol. 2005; 174: 14-20.
11. Maru S, Abe T, Shinohara N et al. Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study. Int. J. Urol. 2012; 19: 110-6.
12. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J. Clin. Oncol. 1992; 10: 1066-73.
13. Logothetis CJ, Finn LD, Smith T et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J. Clin. Oncol. 1995; 13: 2272-7.
14. Rinaldi M, Belvedere O, Cauchi C, Defferrari C, Viola G, Grossi F. Maintenance chemotherapy in non-small cell lung cancer. Ann. Oncol. 2006; 17 (Suppl 2): ii67-70.
15. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating noncross-resistant chemotherapy. Cancer Treat. Rep. 1982; 66: 439-9.
16. Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res. 1986; 46: 3876-85.
17. Clark PE, Agarwal N, Biagioli MC et al. National Comprehensive Cancer Network (NCCN). Bladder Cancer. J. Natl. Compr. Canc. Netw. 2013; 11: 446-75.
18. Bozcuk H, Artac M, Ozdogan M, Savas B. Does Maintenance/Consolidation Chemotherapy Have a Role in the Management of Small Cell Lung Cancer (SCLC)? A Metaanalysis of the Published Randomized Controlled Trials. Cancer 2005; 104: 2650-7.
19. Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-63.
20. Herzog TJ, Coleman RL, Markman M et al. The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol. Oncol. 2006; 102: 218-25.
21. von der Maase H . Gemcitabine-containing regimens in bladder cancer: a new standard of care. Sem. Oncol. 2001; 28 (Suppl 10): 1-3.
22. Lehmann J, Retz M, Siemer S, Schreier U, Zwergel U, Stöckle M. Long-term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma. Int. J. Urol. 2006; 13: 1035-6.
23. Matsuyama H, Yamakawa G, Hirata H. Metastatic urothelial cancer showing an efficacy by low-dose cisplatin. Int. J. Urol. 2002; 9: 272-5.
24. Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int. J. Urol. 2013; 20: 161-71.
25. Hitier-Berthault M, Ansquer C, Branchereau J et al. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study. Int. J. Urol. 2013; 20: 788-96.